Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of CorMedix, Inc. (NYSE: CRMD) ("CorMedix" or "the Company"). The investigation concerns whether the Company violated specific sections of the Securities Exchange Act of 1934 by issuing materially misleading information to the investing public. CorMedix is a pharmaceutical company, that intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. On June 29, 2015, SeekingAlpha.com published a report on CorMedix alleging, among other things, that: (1) CorMedix's only viable product in development is based on a 1970s-era chemical product acquired for less than $1 million in a bankruptcy sale; (2) CorMedix relies heavily on paid stock promoters to pump the stock's value; (3) CorMedix uses misleading clinical data to hide the fact that its Neutrolin/Taurolidine product is a failure; and (4) the Company is led by an alleged "wipeout artist," and associated with partners that have been barred from the securities business by FINRA. On this news, shares of CorMedix fell $0.81 per share, or 16%, to close on June 29, 2015 at $4.05 per share. If you purchased Cormedix shares prior to June 29, 2015, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Get the Investing Edge.
Join Jim Cramer's Members-Only Investing Club
Become an Action Alerts PLUS member to learn from the pros how to invest wisely
and build a customized portolio of blue chip stocks.
Uncover New Investment Opportunities With Our Team of Experts
Jim Cramer and his army of Wall Street pros serve up new trading ideas and in-depth market analysis every day.
More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.

21st Century Fox Scoops Up Local News Stations
Twenty-First Century Fox is making a play for more local stations.

Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.

Three-Part FREE Webinar Series
Joe Burgoyne of the Options Industry Council brings you over 30 years of experience in the financial industry. Join us for Part 1 on Wednesday, March 7 at 7 p.m. EST.

March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.